TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20540639

Group type: EXPERIMENTAL
Intervention: Keto acids‐supplemented low‐protein diet (sLP: 0.6‐0.8 g/kg IBW/d + 0.12 g/kg IBW/d of keto acids, n = 12)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Low protein diet (LP: 0.6‐0.8 g/kg IBW/d, n = 13)
Number of subjects: 39

Group type: COMPARATOR
Intervention: High protein diet (HP: 1.0‐1.2 g/kg IBW/d, n = 14)
Number of subjects: 39
Study: 18988153

Group type: EXPERIMENTAL
Intervention: Mersilene mesh (Group A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Autogenous fascia lata (Group B)
Number of subjects: 31
Study: 16673835

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy plus education intervention
Number of subjects: 59

Group type: COMPARATOR
Intervention: Education-only intervention
Number of subjects: 59
Study: 12722741

Group type: EXPERIMENTAL
Intervention: 111In labelling (0.74 MBq)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 99mTc‐HMPAO labelling (18.5 MBq)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (DCs not incubated with MPL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MPL+ subgroup (both groups)
Number of subjects: 12
Study: 10569461

Group type: EXPERIMENTAL
Intervention: Active filter
Number of subjects: 42

Group type: COMPARATOR
Intervention: Inactive filter
Number of subjects: 42

Group type: COMPARATOR
Intervention: No filter
Number of subjects: 42
Study: 8678510

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) with leucovorin (LV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bolus i.v. infusion of 5‐FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protracted i.v. infusion of 5‐FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New camptothecin derivative CPT‐11
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tomudex (pure TS inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of low‐dose cisplatin and 5‐FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New dihydropyrimidine dehydrogenase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New TS inhibitors
Number of subjects: 0
Study: 1905621

Group type: EXPERIMENTAL
Intervention: ponalrestat 600 mg once daily for 6 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 6754120

Group type: EXPERIMENTAL
Intervention: 12 weeks of isoniazid
Number of subjects: 28000

Group type: EXPERIMENTAL
Intervention: 24 weeks of isoniazid
Number of subjects: 28000

Group type: EXPERIMENTAL
Intervention: 52 weeks of isoniazid
Number of subjects: 28000

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28000
Study: 31868210

Group type: EXPERIMENTAL
Intervention: Improvement in Carbohydrate Quality Index (CQI)
Number of subjects: 5373

Group type: EXPERIMENTAL
Intervention: CQI quintile 5 compared to quintile 1
Number of subjects: 5373
Study: 30948516

Group type: EXPERIMENTAL
Intervention: Bilateral internal thoracic arteries (BITA)
Number of subjects: 3102

Group type: COMPARATOR
Intervention: Single internal thoracic arteries (SITA)
Number of subjects: 3102
Study: 29986562

Group type: EXPERIMENTAL
Intervention: Standard antibiotics (B group)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prolonged antibiotics (C group)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No antibiotics (A group)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Standard antibiotics (E group)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prolonged antibiotics (F group)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No antibiotics (D group)
Number of subjects: 6
Study: 27470088

Group type: EXPERIMENTAL
Intervention: Bromelain (500 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diclofenac (100 mg/day)
Number of subjects: 40
Study: 24407913

Group type: EXPERIMENTAL
Intervention: Smooth Pursuit Training (SPT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Visual Scanning Training (VST)
Number of subjects: 24
Study: 22211833

Group type: EXPERIMENTAL
Intervention: 4 units FFP
Number of subjects: 43

Group type: COMPARATOR
Intervention: 2 units FFP plus 2 g fibrinogen concentrate
Number of subjects: 43
Study: 20439791

Group type: EXPERIMENTAL
Intervention: Prenatal and infancy home visits by nurses
Number of subjects: 613

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 613
Study: 18030102

Group type: EXPERIMENTAL
Intervention: Continence nurse intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care by general practitioner
Number of subjects: 51
Study: 16091379

Group type: EXPERIMENTAL
Intervention: Irbesartan (1 mg/kg body weight) daily for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12044433

Group type: EXPERIMENTAL
Intervention: 1 mg of protamine every 100 IU of heparin (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 mg of protamine every 100 IU of heparin (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: None (Group C)
Number of subjects: 60
Study: 10460567

Group type: EXPERIMENTAL
Intervention: 10 ml bupivacaine 0.125% with epinephrine 1/800 000 (group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10 ml saline (group S)
Number of subjects: 20
Study: 7637642

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 100 mg intramuscularly each month for 6 months
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate treatment
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 148
Study: 2576665

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg three times a day for 4 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once a day for 4 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 31852672

Group type: EXPERIMENTAL
Intervention: 5 mg/day prednisone (maintenance)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Withdrawal of 5 mg/day prednisone
Number of subjects: 124
Study: 29955151

Group type: EXPERIMENTAL
Intervention: SSRI sertraline
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 28796934

Group type: EXPERIMENTAL
Intervention: Candesartan for 6 months
Number of subjects: 124
Study: 25134887

Group type: EXPERIMENTAL
Intervention: English only (EO) treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bilingual skills in Spanish and English (BI) treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nonlinguistic cognitive processing (NCP) treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Spanish language skills
Number of subjects: 48
Study: 22290266

Group type: EXPERIMENTAL
Intervention: D2 receptor occupancy >77%
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: D2 receptor occupancy >80%
Number of subjects: 410
Study: 22011387

Group type: EXPERIMENTAL
Intervention: IG1: invitation letter to participate in the screening
Number of subjects: 20994

Group type: EXPERIMENTAL
Intervention: IG2: invitation letter and informative leaflet
Number of subjects: 20994

Group type: EXPERIMENTAL
Intervention: IG3: invitation letter, informative leaflet and a phone call reminder
Number of subjects: 20994

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20994
Study: 18356336

Group type: EXPERIMENTAL
Intervention: Maternal night blindness
Number of subjects: 12829
Study: 16971716

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 712

Group type: COMPARATOR
Intervention: Uncoated stents
Number of subjects: 712
Study: 14508027

Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC) intervention for 15 weeks (three 45 minute classes per week)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC) intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 36
Study: 10720294

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) therapy
Number of subjects: 45
Study: 8633944

Group type: EXPERIMENTAL
Intervention: Prophylactic high-dose aprotinin (group 1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Postoperative low-dose aprotinin (group 2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nonmedicated control group (group 3)
Number of subjects: 75
Study: 1444728

Group type: EXPERIMENTAL
Intervention: Amantadine (300 mg/d)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Desipramine (150 mg/d)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 6534186

Group type: EXPERIMENTAL
Intervention: Environmental support contracting
Number of subjects: 88

Group type: COMPARATOR
Intervention: Routine, eclectic, 28-d inpatient alcoholism treatment program
Number of subjects: 88
Study: 31607468

Group type: COMPARATOR
Intervention: WHO's recommended regimen (daily UNIMMAP containing 60 mg iron)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: 60 mg screen-and-treat approach (daily UNIMMAP containing 60 mg iron for 7 days if weekly hepcidin was <2.5 μg/L)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: 30 mg screen-and-treat approach (daily UNIMMAP containing 30 mg iron for 7 days if weekly hepcidin was <2.5 μg/L)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: 60 mg screen-and-treat approach
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: 30 mg screen-and-treat approach
Number of subjects: 498
Study: 28292572

Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline (HS)
Number of subjects: 102

Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 102
Study: 26289604

Group type: EXPERIMENTAL
Intervention: Preferred intensity exercise intervention
Number of subjects: 26
Study: 24927595

Group type: EXPERIMENTAL
Intervention: Economic resource scarcity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual representations of African American faces under scarcity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face representations produced under scarcity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 22013152

Group type: EXPERIMENTAL
Intervention: Reperfusion therapy
Number of subjects: 533

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 533
Study: 20642296

Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus acidophilus DDS‐1, Bifidobacterium lactis UABLA‐12 with fructo‐oligosaccharide at a dosage of 5 billion colony‐forming units twice daily for 8 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 90
Study: 18500527

Group type: EXPERIMENTAL
Intervention: Dynamic MR imaging at 3.0 T
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dynamic MR imaging at 1.5 T
Number of subjects: 10
Study: 15986013

Group type: EXPERIMENTAL
Intervention: New immunosuppressive agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modern immunosuppression strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various combination protocols
Number of subjects: 0
Study: 11886964

Group type: EXPERIMENTAL
Intervention: Rehabilitation
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control
Number of subjects: 103
Study: 10461056

Group type: COMPARATOR
Intervention: Prophylactic CHPP
Number of subjects: 32

Group type: COMPARATOR
Intervention: Therapeutic CHPP
Number of subjects: 32
Study: 7780071

Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 2.5 microgram/kg/min for 40 minutes (hydrated group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dopamine infusion at 2.5 microgram/kg/min for 40 minutes (nonhydrated group)
Number of subjects: 10
Study: 2310656

Group type: EXPERIMENTAL
Intervention: Cromakalim (15 micrograms kg‐1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 490882

Group type: EXPERIMENTAL
Intervention: Stepped Care (SC)
Number of subjects: 10940

Group type: COMPARATOR
Intervention: Referred Care (RC)
Number of subjects: 10940
Study: 31566320

Group type: EXPERIMENTAL
Intervention: Orchid drug-coated balloon (DCB)
Number of subjects: 74

Group type: COMPARATOR
Intervention: PTA (standard percutaneous transluminal angioplasty)
Number of subjects: 74
Study: 28339546

Group type: EXPERIMENTAL
Intervention: FIRM-PVI
Number of subjects: 625

Group type: COMPARATOR
Intervention: PVI-controls
Number of subjects: 625
Study: 25227499

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 441

Group type: COMPARATOR
Intervention: Bevacizumab 1.25 mg
Number of subjects: 441
Study: 23326457

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Novel biomarkers (Copeptin, MR-proADM, MR-proANP)
Number of subjects: 405
Study: 21915733

Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 0.5 g
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 1.0 g
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 2.0 g
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefotetan disodium (all doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of R-CTT and S-CTT
Number of subjects: 12
Study: 18324419

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal vaccine (PV) in group 1 (nephrotic children on high-dose prednisone)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal vaccine (PV) in group 2 (patients in remission)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No vaccination in group 3 (control group)
Number of subjects: 30
Study: 16224150

Group type: EXPERIMENTAL
Intervention: Fas-positive cases
Number of subjects: 110

Group type: COMPARATOR
Intervention: Fas-negative cases
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: NSCLC patients
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: p53 and bcl-2 overexpressions
Number of subjects: 110
Study: 12384635

Group type: EXPERIMENTAL
Intervention: Eptifibatide (Integrilin™, COR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10545309

Group type: COMPARATOR
Intervention: beta-blocker therapy (atenolol or metoprolol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 20
Study: 8669218

Group type: EXPERIMENTAL
Intervention: 20 mg methylnaltrexone IV at the end of surgery
Number of subjects: 120
Study: 2180344

Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 27

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 27
Study: 500844

Group type: EXPERIMENTAL
Intervention: Telephone follow-up method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mail follow-up method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face-to-face interview method
Number of subjects: 0

Group type: COMPARATOR
Intervention: All methods
Number of subjects: 0
Study: 31185027

Group type: EXPERIMENTAL
Intervention: Unadjusted model for 60-s measure
Number of subjects: 1735

Group type: EXPERIMENTAL
Intervention: Best-fit model with covariates (age, sex, years of schooling, time of day)
Number of subjects: 1735

Group type: EXPERIMENTAL
Intervention: First quartile of word generation
Number of subjects: 1735

Group type: EXPERIMENTAL
Intervention: Second quartile of word generation
Number of subjects: 1735

Group type: EXPERIMENTAL
Intervention: Third quartile of word generation
Number of subjects: 1735

Group type: EXPERIMENTAL
Intervention: Fourth quartile of word generation
Number of subjects: 1735

Group type: EXPERIMENTAL
Intervention: Average production starting point (intercept)
Number of subjects: 1735

Group type: EXPERIMENTAL
Intervention: Production decay (slope)
Number of subjects: 1735
Study: 28966188

Group type: EXPERIMENTAL
Intervention: Digital impressions using intraoral optical scanning (IOS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional impressions
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Digital impressions using IOS
Number of subjects: 50
Study: 26010066

Group type: EXPERIMENTAL
Intervention: Incongruent trajectories based on animacy cues (frog-like and jumping-like trajectories)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incongruent trajectories not based on animacy cues (bouncing and rotating)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulation of speed ratio between movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulation of temporal delay between movements
Number of subjects: 0
Study: 23180157

Group type: EXPERIMENTAL
Intervention: HPV6/11/16/18 vaccine
Number of subjects: 1749

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1749

Group type: COMPARATOR
Intervention: Unvaccinated reference cohort
Number of subjects: 1749
Study: 22333107

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Hyperbaric air therapy (Control)
Number of subjects: 119
Study: 19617208

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G‐CSF) at a dosage of 1 microg/kg/day starting on the sixth day after ovulation.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G‐CSF)
Number of subjects: 68
Study: 18085968

Group type: EXPERIMENTAL
Intervention: Chinese Internet Addiction Inventory (CIAI)
Number of subjects: 1029
Study: 15128683

Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications (PIMs) prescribed to seniors
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Short-acting benzodiazepines prescribed for longer than 30 days
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Oxybutynin prescriptions
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Gender of patients (women)
Number of subjects: 889
Study: 11160548

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fortified bread
Number of subjects: 16
Study: 9787605

Group type: EXPERIMENTAL
Intervention: Zidovudine immediately after randomisation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo until condition deteriorates (Control)
Number of subjects: 0
Study: 8067217

Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.25%, 0.5%, 0.75% and 1%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25%, 0.5% and 0.75%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ropivacaine with adrenaline (5 ug.ml‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline (5 ug.ml‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ropivacaine (plain solutions)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bupivacaine (plain solutions)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ropivacaine and bupivacaine with adrenaline
Number of subjects: 10
Study: 3394912

Group type: EXPERIMENTAL
Intervention: Lignocaine 2% with adrenaline 1:200,000
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with adrenaline 1:200,000
Number of subjects: 38

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 38
Study: 31301451

Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT) capsules (induction dose of 30 capsules at week 4 and maintenance dose of 12 capsules at week 8)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 22
Study: 30115933

Group type: EXPERIMENTAL
Intervention: Optimum cardiovascular health (CVH) status
Number of subjects: 3487

Group type: EXPERIMENTAL
Intervention: Ideal physical activity
Number of subjects: 3487

Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 3487

Group type: EXPERIMENTAL
Intervention: Fasting blood glucose
Number of subjects: 3487
Study: 28655086

Group type: EXPERIMENTAL
Intervention: SMT‐Ⅱ video laryngoscope
Number of subjects: 90

Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope
Number of subjects: 90
Study: 25616438

Group type: EXPERIMENTAL
Intervention: n-3 FA supplementation (1.7 g DHA and 0.6 g EPA daily for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24169736

Group type: EXPERIMENTAL
Intervention: Dance-based exercise therapy (1 hour)
Number of subjects: 30
Study: 21958585

Group type: EXPERIMENTAL
Intervention: Mepolizumab (750 mg, 2 single intravenous injections, 28 days apart)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18986283

Group type: EXPERIMENTAL
Intervention: Appropriate antimicrobial treatment for mild CAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ineffective therapies or no therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite outcome assessments
Number of subjects: 0
Study: 15118778

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 50
Study: 11449032

Group type: EXPERIMENTAL
Intervention: 30 mg/day of methylphenidate (MPH)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9554249

Group type: EXPERIMENTAL
Intervention: Group 1: Combination of 50 micrograms ethinyl estradiol and 1 mg norethindrone per tablet on days 6-10, and 0.70 mg norethindrone only on days 11-19. Placebo on days 1-5 and 20-28.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Group 2: Combination of 50 micrograms ethinyl estradiol and 1 mg norethindrone per tablet on days 8-12, and 0.70 mg norethindrone only on days 13-21. Placebo on days 1-7 and 22-28.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both groups (1 and 2)
Number of subjects: 10
Study: 8046139

Group type: EXPERIMENTAL
Intervention: Presenting the masker to both ears and signal to one ear
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Playing different masker samples sequentially in each interval of every trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presenting the signal in alternate bursts of multiple, identical masker samples
Number of subjects: 0
Study: 2977393

Group type: EXPERIMENTAL
Intervention: 2.5 mg amlodipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg amlodipine
Number of subjects: 12